Selling Replimune Group Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Despite the fact that Replimune Group, Inc.'s (NASDAQ:REPL) value has dropped 12% in the last week insiders who sold US$1.6m worth of stock in the past 12 months have had less success. Insiders might
Replimune Group Provides Interim Results for Skin Cancer Therapy
Replimune Group (REPL) said Sunday that a phase 1/2 clinical trial of its RP1 monotherapy for skin cancer has initially showed an overall response rate of 34.8%. The interim overall response rate come
Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024
In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partia
Interim Results From the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients With Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego.
Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)
Replimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEO
Replimune Names Sushil Patel as CEO in Broader Shakeup
By Will Feuer Replimune Group, a clinical-stage biotechnology company, named Sushil Patel as its next chief executive officer, succeeding Philip Astley-Sparke, who will become executive chairman. Th
Replimune Group Announces CEO Transition
Replimune Appoints Sushil Patel To CEO Succeeding Philip Astley-sparke Effective April 1, 2024. Mr. Astley-sparke Will Transition From His Current Role As CEO To Executive Chairman Of The Board Of Director
Replimune Appoints Sushil Patel To CEO Succeeding Philip Astley-sparke Effective April 1, 2024. Mr. Astley-sparke Will Transition From His Current Role As CEO To Executive Chairman Of The Board Of Dir
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced
Replimune to Present at Three Upcoming Investor Conferences
WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapie
Is Replimune Group, Inc. (NASDAQ:REPL) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$6.45 Replimune Group's US$8.61 share price signals that it might be 33% overvalued Analyst price
Positive Outlook for Replimune Group With Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating
Replimune Group (REPL) has an average rating of outperform and price targets ranging from $10 to $19, according to analysts polled by Capital IQ.
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
Replimune Group Is Worried About This – Should You Be Worried Too?
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
Replimune Group: Q3 Earnings Insights
Replimune Group (NASDAQ:REPL) reported its Q3 earnings results on Thursday, February 8, 2024 at 08:00 AM.Here's what investors need to know about the announcement.EarningsReplimune Group beat estimate
Replimune Group Q3 EPS $(0.77) Beats $(0.93) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.93) by 17.2 percent. This is a 11.59 percent decrease over losses of $(0.6
Replimune Group Cash Runway Extended to Fund Ops Into 2H 2026 >REPL
Replimune Group Cash Runway Extended to Fund Ops Into 2H 2026 >REPL
No Data